

## Addendum

**Addendum: Sustained response of three pediatric BRAF<sup>V600E</sup> mutated high-grade gliomas to combined BRAF and MEK inhibitor therapy**

**Stephanie A. Toll<sup>1,2,\*</sup>, Hung N. Tran<sup>3,\*</sup>, Jennifer Cotter<sup>2,4</sup>, Alexander R. Judkins<sup>2,4</sup>, Benita Tamrazi<sup>2,5</sup>, Jaclyn A. Biegel<sup>2,4</sup>, Girish Dhall<sup>1,2</sup>, Nathan J. Robison<sup>1,2</sup>, Kaaren Waters<sup>1</sup>, Palak Patel<sup>2</sup>, Robert Cooper<sup>3,\*</sup> and Ashley S. Margol<sup>1,2,\*</sup>**

<sup>1</sup>Division of Hematology, Oncology and Blood and Marrow Transplantation, Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA, USA

<sup>2</sup>University of Southern California Keck School of Medicine, Los Angeles, CA, USA

<sup>3</sup>Kaiser Permanente Southern California, Los Angeles, CA, USA

<sup>4</sup>Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA, USA

<sup>5</sup>Department of Radiology and Imaging, Children's Hospital Los Angeles, Los Angeles, CA, USA

\*These authors have contributed equally to this work

**Published:** May 19, 2023

**Copyright:** © 2023 Toll et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**This article has an addendum:** Signed HIPPA forms from the parents of the 2 patients who were alive at the time of manuscript submission were obtained.

Original article: Oncotarget. 2019; 10:551–557. <https://doi.org/10.18632/oncotarget.26560>